Fate Therapeutics Inc
FATE
Get informed when a big investor buys or sells
+ FollowMarket Cap$271.58M
Close$
$-0.51
119.9% downside
Current Fair Value
119.9% downsideOvervalued by 119.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $271.58 Million |
|---|---|
| Enterprise Value | $314.83 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.15 |
| Beta | 2.55 |
| Outstanding Shares | 120,397,390 |
Return
| Return on Equity | -82.12% |
|---|---|
| Return on Assets | -48.44% |
| Return on Invested Capital | -58.02% |
Valuation & Multiples
| P/E Ratio | -2.22 |
|---|---|
| PEG | 19.33 |
| Price to Sales | - |
| Price to Book Ratio | 2.56 |
| Enterprise Value to Revenue | 48.5 |
| Enterprise Value to EBIT | -2.38 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$1.94 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$1.34 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4453▼ 28.87% |
|---|---|
| Total Calls | 246,100▲ 207.24% |
| Total Puts | 109,600▲ 86.39% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 60.07%▼ 1.66% |
|---|---|
| Total Invested | $194.59M▲ 118.97% |
| Investors Holding | 158▼ 3.00% |
ESG Score
No data
About Fate Therapeutics Inc
CEO: William Rastetter